Parabilis director converts preferred to common shares
Parabilis Medicines director Edward M. Fitzgerald reported a series of non-cash conversions of preferred stock into common shares.
Rhea-AI Filing Summary
Parabilis Medicines director Edward M. Fitzgerald reported a series of non-cash conversions of preferred stock into common shares. On June 11, 2026, he converted Series B, C and F Preferred Stock into Common Stock, acquiring 5,539, 3,878 and 5,271 common shares, respectively, at $0.00 per share.
These preferred shares automatically converted into common immediately prior to the closing of the company’s initial public offering on June 9, 2026, as described in the footnotes. No shares were sold; all Form 4 transactions are coded as conversions of derivative securities. Following these transactions, Fitzgerald directly holds 14,688 shares of Common Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
17,109 shares exercised/converted
Exercise
6 txns
Insider
FITZGERALD EDWARD M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Preferred Stock | 5,332 | $0.00 | $0.00 |
| Conversion | Series C Preferred Stock | 3,666 | $0.00 | $0.00 |
| Conversion | Series F Preferred Stock | 8,111 | $0.00 | $0.00 |
| Conversion | Common Stock | 5,539 | $0.00 | $0.00 |
| Conversion | Common Stock | 3,878 | $0.00 | $0.00 |
| Conversion | Common Stock | 5,271 | $0.00 | $0.00 |
Holdings After Transaction:
Series B Preferred Stock — 0 contracts (Direct);
Series C Preferred Stock — 0 contracts (Direct);
Series F Preferred Stock — 0 contracts (Direct);
Common Stock — 14,688 shares (Direct)
Footnotes (3)
- F1. Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date.
- F2. Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date.
- F3. Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date.
Key Figures
Common shares from Series B conversion: 5,539 shares
Common shares from Series C conversion: 3,878 shares
Common shares from Series F conversion: 5,271 shares
+2 more
5 metrics
Common shares from Series B conversion
5,539 shares
Non-derivative acquisition on June 11, 2026 via conversion
Common shares from Series C conversion
3,878 shares
Non-derivative acquisition on June 11, 2026 via conversion
Common shares from Series F conversion
5,271 shares
Non-derivative acquisition on June 11, 2026 via conversion
Common shares held after transactions
14,688 shares
Direct common stock ownership following June 11, 2026 conversions
Preferred conversion activity
3 derivative conversions, 17,109 shares
ExerciseShares in transactionSummary for June 11, 2026
Key Terms
Conversion of derivative security, Series B Preferred Stock, Series C Preferred Stock, Series F Preferred Stock, +1 more
5 terms
Conversion of derivative security financial
"Each transaction is coded as a C with description "Conversion of derivative security"."
Series B Preferred Stock financial
"Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis."
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Series C Preferred Stock financial
"Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis."
A Series C preferred stock is a specific class of ownership issued during a later funding round that gives holders priority over common shareholders for getting paid and receiving dividends, like having a reserved lane in traffic when money is distributed. It often includes agreed rights such as a fixed payout, protection against dilution, and the option to convert into common shares, so investors treat it as a mix of safety and upside potential.
Series F Preferred Stock financial
"Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis."
Series F preferred stock is a class of company shares that gives holders priority over common shareholders for dividend payments and for getting money back if the company is sold or liquidated, much like a ticket that moves you to the front of the line. These shares often carry a fixed dividend and special rights—sometimes including conversion into common stock—so investors consider them when weighing income, downside protection and potential ownership dilution.
initial public offering financial
"Preferred shares automatically converted immediately prior to the closing of the Issuer's initial public offering on June 9, 2026."
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Parabilis Medicines (PBLS) director Edward M. Fitzgerald report on this Form 4?
He reported non-cash conversions of preferred stock into common shares. On June 11, 2026, several series of preferred stock automatically converted into common in connection with Parabilis Medicines’ IPO, increasing his direct common stock holdings without any open-market purchases or sales.
Did Edward M. Fitzgerald buy or sell Parabilis Medicines (PBLS) stock in the market?
No, he neither bought nor sold shares in the open market. All reported transactions are coded as conversions of derivative securities, meaning preferred stock automatically converted into common stock, with no transaction price and no reported cash proceeds changing hands.
What is Edward M. Fitzgerald’s Parabilis Medicines (PBLS) common stock position after these transactions?
After the reported conversions, his direct ownership stands at 14,688 common shares. This figure comes from the post-transaction “amount of securities beneficially owned” column, which reflects his direct common stock holdings following the automatic preferred-to-common conversions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
